Troglitazone is a synthetic antidiabetic and anti-inflammatory drug previously prescribed to patients with type 2 diabetes mellitus, but was withdrawn from the market in 2000 due to toxicity issues. Selective agonist of the peroxisome proliferator-activated receptor-γ (PPARγ, EC50=555nM) with no activity for PPARα or PPARδ.